
Ruben L Smeets

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3765893/publications.pdf Version: 2024-02-01



PUREN I SMEETS

#	Article	IF	CITATIONS
1	Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application. Journal of Translational Autoimmunity, 2022, 5, 100141.	4.0	8
2	Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19. Journal of Infectious Diseases, 2021, 223, 1322-1333.	4.0	61
3	Autoantibody profiles in systemic sclerosis; a comparison of diagnostic tests. Autoimmunity, 2021, 54, 148-155.	2.6	17
4	Blood-Based Immune Profiling Combined with Machine Learning Discriminates Psoriatic Arthritis from Psoriasis Patients. International Journal of Molecular Sciences, 2021, 22, 10990.	4.1	6
5	Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels. Autoimmunity Reviews, 2020, 19, 102515.	5.8	17
6	TNFα-Signaling Modulates the Kinase Activity of Human Effector Treg and Regulates IL-17A Expression. Frontiers in Immunology, 2019, 10, 3047.	4.8	14
7	Single CD28 stimulation induces stable and polyclonal expansion of human regulatory T cells. Scientific Reports, 2017, 7, 43003.	3.3	41
8	Targeting PKC in Human T Cells Using Sotrastaurin (AEB071) Preserves Regulatory T Cells and Prevents IL-17 Production. Journal of Investigative Dermatology, 2014, 134, 975-983.	0.7	37
9	Smartphoneâ€based analysis of biochemical tests for health monitoring support at home. Healthcare Technology Letters, 2014, 1, 92-97.	3.3	11
10	Fully-automated interpretation of biochemical tests for decision support by smartphones. , 2012, , .		7
11	Molecular pathway profiling of T lymphocyte signal transduction pathways; Th1 and Th2 genomic fingerprints are defined by TCR and CD28-mediated signaling. BMC Immunology, 2012, 13, 12.	2.2	45
12	Org 214007-0: A Novel Non-Steroidal Selective Glucocorticoid Receptor Modulator with Full Anti-Inflammatory Properties and Improved Therapeutic Index. PLoS ONE, 2012, 7, e48385.	2.5	26
13	Mycophenolic Acid-Mediated Suppression of Human CD4+ T Cells: More Than Mere Guanine Nucleotide Deprivation. American Journal of Transplantation, 2011, 11, 439-449.	4.7	70
14	Increased expression of interleukin-22 by synovial Th17 cells during late stages of murine experimental arthritis is controlled by interleukin-1 and enhances bone degradation. Arthritis and Rheumatism, 2011, 63, 2939-2948.	6.7	60
15	Structure-based lead identification of ATP-competitive MK2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3818-3822.	2.2	22
16	Increased IL-22 expression by synovial Th17 cells during late stages of arthritis is controlled by IL-1 and enhances bone degradation. Annals of the Rheumatic Diseases, 2011, 70, A51-A52.	0.9	0
17	The natural soluble form of IL-18 receptor β exacerbates collagen-induced arthritis via modulation of T-cell immune responses. Annals of the Rheumatic Diseases, 2010, 69, 276-283.	0.9	30
18	Literature Mining for the Discovery of Hidden Connections between Drugs, Genes and Diseases. PLoS Computational Biology, 2010, 6, e1000943.	3.2	138

RUBEN L SMEETS

#	Article	IF	CITATIONS
19	Splenic suppressor of cytokine signaling 3 transgene expression affects T cell responses and prevents development of collagenâ€induced arthritis. Arthritis and Rheumatism, 2008, 58, 3742-3752.	6.7	35
20	A potent and selective p38 inhibitor protects against bone damage in murine collagenâ€induced arthritis: a comparison with neutralization of mouse TNFα. British Journal of Pharmacology, 2008, 154, 153-164.	5.4	50
21	Tumor marker nucleoporin 88kDa regulates nucleocytoplasmic transport of NF-κB. Biochemical and Biophysical Research Communications, 2008, 374, 424-430.	2.1	37
22	Human CD25highFoxp3pos regulatory T cells differentiate into IL-17–producing cells. Blood, 2008, 112, 2340-2352.	1.4	672
23	A novel role for suppressor of cytokine signaling 3 in cartilage destruction via induction of chondrocyte desensitization toward insulin-like growth factor. Arthritis and Rheumatism, 2006, 54, 1518-1528.	6.7	45
24	Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Arthritis and Rheumatism, 2005, 52, 2202-2211.	6.7	43
25	Title is missing!. Arthritis Research, 2005, 7, P66.	2.0	Ο
26	Title is missing!. Arthritis Research, 2005, 7, P89.	2.0	0
27	An inflammation-inducible adenoviral expression system for local treatment of the arthritic joint. Gene Therapy, 2004, 11, 581-590.	4.5	55
28	Crucial role of synovial lining macrophages in the promotion of transforming growth factor ?-mediated osteophyte formation. Arthritis and Rheumatism, 2004, 50, 103-111.	6.7	161
29	Gene therapy in animal models of rheumatoid arthritis: are we ready for the patients?. Arthritis Research, 2004, 6, 183.	2.0	18
30	Interleukin-18 Promotes Joint Inflammation and Induces Interleukin-1-Driven Cartilage Destruction. American Journal of Pathology, 2004, 165, 959-967.	3.8	87
31	Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis. Arthritis and Rheumatism, 2003, 48, 2949-2958.	6.7	42
32	Adenoviral delivery of IL-18 binding protein C ameliorates Collagen-Induced Arthritis in mice. Gene Therapy, 2003, 10, 1004-1011.	4.5	273
33	Deficiency of NADPH Oxidase Components p47phox and gp91phox Caused Granulomatous Synovitis and Increased Connective Tissue Destruction in Experimental Arthritis Models. American Journal of Pathology, 2003, 163, 1525-1537.	3.8	83
34	Toll-Like Receptor 2 Pathway Drives Streptococcal Cell Wall-Induced Joint Inflammation: Critical Role of Myeloid Differentiation Factor 88. Journal of Immunology, 2003, 171, 6145-6153.	0.8	199